[Asia Economy Reporter Lee Seon-ae]ISU Abxis announced on the 25th that it has received a patent decision from the China National Intellectual Property Administration (CNIPA) for 'ISU104,' which is being developed to target 'ErbB3' positive cancer.
The patent pertains to 'an antibody that specifically binds to ErbB3 for the treatment of cancers with activated or overexpressed ErbB3 and resistant to anticancer drugs inhibiting ErbB1 or ErbB2.'
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
